<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2517">
  <stage>Registered</stage>
  <submitdate>29/09/2009</submitdate>
  <approvaldate>29/09/2009</approvaldate>
  <nctid>NCT00987454</nctid>
  <trial_identification>
    <studytitle>Erythropoietin in Traumatic Brain Injury (EPO-TBI)</studytitle>
    <scientifictitle>A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury</scientifictitle>
    <utrn />
    <trialacronym>EPO-TBI</trialacronym>
    <secondaryid>ANZIC-RC/RB002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Traumatic Brain Injury</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Epoetin Alfa
Treatment: drugs - Sodium Chloride 0.9%

Active Comparator: Erythropoietin - Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.

Placebo Comparator: Placebo - Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.


Treatment: drugs: Epoetin Alfa
40,000 IU given as subcutaneous injection weekly up to 3 doses

Treatment: drugs: Sodium Chloride 0.9%
1 m/L given as subcutaneous injection weekly up to 3 doses

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Combined proportion of unfavourable neurological outcomes at 6 months: severe disability (defined as GOSE scores 2-4) or death (GOSE score 1).</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Probability of an equal or greater Glasgow Coma Scale Extended (GOSE) level at 6 months compared to the probability of a lesser GOSE level, using a proportional odds model</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of surviving patients with unfavourable neurological outcome (GOSE 2-4) at 6 months</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life assessment (SF-12 and EQ-5D) at 6 months</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality at 6 months</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of proximal deep venous thrombosis detected during screening by compression Doppler ultrasound</outcome>
      <timepoint>21 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with composite thrombotic vascular events (DVT, pulmonary embolus, myocardial infarction, cardiac arrest and cerebrovascular events) at 6 months</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost effectiveness analysis at 6 months (based on EQ-5D)</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Are = 15 to = 65 years of age

          -  Are &lt; 24 hours since primary traumatic injury

          -  Are expected to stay = 48 hours

          -  Have a haemoglobin not exceeding the upper limit of the applicable normal (ULN)
             reference range in clinical use at the treating institution

          -  Have written informed consent from legal surrogate</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  GCS = 3 and fixed dilated pupils

          -  History of DVT, PE or other thromboembolic event

          -  A chronic hypercoagulable disorder, including known malignancy

          -  Treatment with EPO in the last 30 days

          -  First dose of study drug unable to be given within 24 hours of primary injury

          -  Pregnancy or lactation or 3 months post partum

          -  Uncontrolled hypertension (systolic blood pressure of &gt;200 mm Hg or diastolic blood
             pressure of &gt;110 mm Hg)

          -  Acute myocardial infarct

          -  Expected to die imminently (&lt; 24 hours)

          -  Inability to perform lower limb ultrasounds

          -  Known sensitivity to mammalian cell derived products

          -  Hypersensitivity to the active substance or to any of the additives

          -  Pure red cell aplasia (PRCA)

          -  End stage renal failure (receives chronic dialysis)

          -  Severe pre-existing physical or mental disability or severe co-morbidity that may
             interfere with the assessment of outcome

          -  Spinal cord injury

          -  Treatment with any investigational drug within 30 days before enrolment

          -  The treating physician believes it is not in the best interest of the patient to be
             randomised to this trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>606</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Canberra</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>St Vincent's Hospital Sydney - Darlinghurst</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>John Hunter Hospital - Newcastle</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Gold Coast University Hospital - Southport</hospital>
    <hospital>The Townsville Hospital - Townsville</hospital>
    <hospital>Royal Adelaide Hosptial - Adelaide</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2605 - Canberra</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2305 - Newcastle</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>4814 - Townsville</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3050 - Melbourne</postcode>
    <postcode>3181 - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>NÃ®mes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>South Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Australian and New Zealand Intensive Care Research Centre</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Intensive Care Society Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study seeks to determine if erythropoietin alpha (EPO) administered to adult critical
      care patients with moderate or severe traumatic brain injury improves neurological function
      assessed at six months after injury.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00987454</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alistair D Nichol, MD</name>
      <address>Monash University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>